Amgen Defends $70M Biosimilar Verdict Against Hospira
Amgen Inc. on Wednesday defended its $70 million patent infringement verdict against post-trial attacks from Hospira, telling a Delaware federal judge that a regulatory safe harbor for limited manufacturing of the...To view the full article, register now.
Already a subscriber? Click here to view full article